SCHEMBL5494305

SCHEMBL5494305

COc1ccc(N)cc1-c1ccc2nc(N)ncc2c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LCK P06239 4/20 0.56
KDR P35968 2/20 0.56
JAK3 P52333 2/20 0.56
MAPK14 Q16539 1/20 0.56
ADORA1 P30542 2/20 0.48
DHFR P00374 4/20 0.48
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
TYK2 P29597 1/20 0.46
AURKB Q96GD4 1/20 0.46
ADORA2A P29274 1/20 0.45
KIT P10721 3/20 0.44
SRC P12931 3/20 0.44
NTRK1 P04629 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
BRAF P15056 1/20 0.42
MAP4K4 O95819 1/20 0.40
FGFR1 P11362 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24335917 0.88 LCK (0.58) LCKKDRJAK3MAPK14ADORA1
SCHEMBL24457804 0.85 BRAF (0.47) LCKKDRJAK3MAPK14DHFR
SCHEMBL5489139 0.82 LCK (0.72) LCKKDRJAK3MAPK14DHFR
SCHEMBL14107922 0.79 NTRK1 (0.52) ADORA1DHFRADORA2AKITNTRK1
SCHEMBL5494034 0.79 LCK (0.56) LCKKDRJAK3MAPK14DHFR
SCHEMBL5492816 0.79 LCK (0.72) LCKKDRJAK3MAPK14DHFR
SCHEMBL5494572 0.79 LCK (0.56) LCKKDRJAK3MAPK14ADORA1
SCHEMBL5491016 0.79 LCK (0.56) LCKKDRJAK3MAPK14ADORA1
SCHEMBL5489026 0.78 LCK (0.55) LCKKDRJAK3MAPK14ADORA1
SCHEMBL19943434 0.77 LCK (0.53) LCKKDRJAK3MAPK14DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP disclosed
EP-1836174-B2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2019-10-02 EP disclosed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP disclosed
EP-1836174-B1 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2013-02-27 EP disclosed
EP-1836174-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC. (US) 2007-09-26 EP disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use AMGEN INC. 2007-03-08 US disclosed
WO-2006039718-A2 ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS AMGEN INC (US) 2006-04-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054916-A1 Aryl nitrogen-containing bicyclic compounds and methods of use MAP3K1, MAP3K5, MAP3K2 LCK 106/4885KDR 1044/4885JAK3 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.